Q-omics provides the consensus-scored KLF4 profile across patient tissues and cancer cell-line models. KLF4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLF4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, KLF4 RNA expression shows 19,207 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where KLF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF4 survival associations across molecular data types. KLF4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF4 RNA expression–survival associations across cancer types. High KLF4 expression shows unfavorable associations in UVM, LUAD and ACC, but favorable associations in KIRC, SCLC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KLF4 RNA expression.
This table summarizes KLF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF4 shows lower tumor expression in COAD, BLCA, KICH, LUAD, BRCA and READ. The COAD box plot shows higher KLF4 RNA expression in normal versus tumor tissue (log2 FC = −2.918, t-test p < 0.001).
This table shows molecular features associated with KLF4 in patient tissues and cancer cell lines. In patient samples, KLF4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
